cd34, mouse, mab mec14.7  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech cd34, mouse, mab mec14.7
    Cd34, Mouse, Mab Mec14.7, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34, mouse, mab mec14.7/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34, mouse, mab mec14.7 - by Bioz Stars, 2024-03
    93/100 stars

    Images

    cd34, mouse, mab mec14.7  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech cd34, mouse, mab mec14.7
    Cd34, Mouse, Mab Mec14.7, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34, mouse, mab mec14.7/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34, mouse, mab mec14.7 - by Bioz Stars, 2024-03
    93/100 stars

    Images

    rat monoclonal anti cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-03
    93/100 stars

    Images

    1) Product Images from "DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells"

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    Journal: bioRxiv

    doi: 10.1101/2023.01.08.523169

    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Figure Legend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Techniques Used: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    cd34, mouse, mab mec14.7  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech cd34, mouse, mab mec14.7
    Cd34, Mouse, Mab Mec14.7, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34, mouse, mab mec14.7/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34, mouse, mab mec14.7 - by Bioz Stars, 2024-03
    93/100 stars

    Images

    cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech cd34 antibody
    A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin). B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin). C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H). D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K). E. Macroscopical changes in paratubarian area (microscopical sections in L–N). F. Cavernous hemangioma featuring focal hyalinization. G. The same tumor mass area with higher magnification (haematoxylin-eosin). H. Weak focal hVEGF-A 165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells. I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently <t>CD34</t> <t>positive</t> lining. I. Hematoxylin-eosin. (an arrow points to an area shown in K) J. CD34 immunostaining. K. The same area as in I with higher magnification (stained with Masson Trichrom). Asterix in I and J indicate the same area. L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A 165 immunopositivity shown in N. (hVEGF-A 165 immunostaining). Bar : F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.
    Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34 antibody - by Bioz Stars, 2024-03
    93/100 stars

    Images

    1) Product Images from "Short and Long-Term Effects of hVEGF-A 165 in Cre-Activated Transgenic Mice"

    Article Title: Short and Long-Term Effects of hVEGF-A 165 in Cre-Activated Transgenic Mice

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0000013

    A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin). B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin). C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H). D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K). E. Macroscopical changes in paratubarian area (microscopical sections in L–N). F. Cavernous hemangioma featuring focal hyalinization. G. The same tumor mass area with higher magnification (haematoxylin-eosin). H. Weak focal hVEGF-A 165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells. I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently CD34 positive lining. I. Hematoxylin-eosin. (an arrow points to an area shown in K) J. CD34 immunostaining. K. The same area as in I with higher magnification (stained with Masson Trichrom). Asterix in I and J indicate the same area. L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A 165 immunopositivity shown in N. (hVEGF-A 165 immunostaining). Bar : F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.
    Figure Legend Snippet: A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin). B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin). C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H). D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K). E. Macroscopical changes in paratubarian area (microscopical sections in L–N). F. Cavernous hemangioma featuring focal hyalinization. G. The same tumor mass area with higher magnification (haematoxylin-eosin). H. Weak focal hVEGF-A 165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells. I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently CD34 positive lining. I. Hematoxylin-eosin. (an arrow points to an area shown in K) J. CD34 immunostaining. K. The same area as in I with higher magnification (stained with Masson Trichrom). Asterix in I and J indicate the same area. L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A 165 immunopositivity shown in N. (hVEGF-A 165 immunostaining). Bar : F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.

    Techniques Used: Immunostaining, Staining

    cd34  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech cd34
    Panels A and B show representative examples of IHC for the hypoxia marker MCT4 in control and cabozantinib-treated tumor bearing animals. Hypoxia in compact tumor regions is significantly increased after treatment (Students t -test, p = 0.003, panel C). D and E show examples of Ki67 stainings in compact tumor areas. Proliferation indices were significantly different in these regions (Students t- test p = 0.04), but no difference was detected in diffuse tumor areas (panel F). Panels G and H show representative examples of GLUT-1 vessel staining. Automated quantification revealed no differences between vessel densities of diffuse tumor areas in control vs treated mice (I). Numbers of <t>CD34-positive</t> vessels were lower in cabozantinib treated mice (see panels J and K, arrows point at blood vessels), but these data were not quantified because vessels without <t>CD34</t> expression were also observed in these mice. L: Western blot analysis of protein extracts (50 µg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, though not complete, reduction of c-MET phosphorylation. As a loading control, γ-tubulin was included. Immunohistochemistry for phospho-c-MET (Y1234/1235) also shows the presence of phosphorylated c-MET in treated animals, as visualized in panel K. Size bars: A–B 2 mm, D–E 100 µm, G, H, J, K 200 µm,
    Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34 - by Bioz Stars, 2024-03
    93/100 stars

    Images

    1) Product Images from "Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2"

    Article Title: Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0058262

    Panels A and B show representative examples of IHC for the hypoxia marker MCT4 in control and cabozantinib-treated tumor bearing animals. Hypoxia in compact tumor regions is significantly increased after treatment (Students t -test, p = 0.003, panel C). D and E show examples of Ki67 stainings in compact tumor areas. Proliferation indices were significantly different in these regions (Students t- test p = 0.04), but no difference was detected in diffuse tumor areas (panel F). Panels G and H show representative examples of GLUT-1 vessel staining. Automated quantification revealed no differences between vessel densities of diffuse tumor areas in control vs treated mice (I). Numbers of CD34-positive vessels were lower in cabozantinib treated mice (see panels J and K, arrows point at blood vessels), but these data were not quantified because vessels without CD34 expression were also observed in these mice. L: Western blot analysis of protein extracts (50 µg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, though not complete, reduction of c-MET phosphorylation. As a loading control, γ-tubulin was included. Immunohistochemistry for phospho-c-MET (Y1234/1235) also shows the presence of phosphorylated c-MET in treated animals, as visualized in panel K. Size bars: A–B 2 mm, D–E 100 µm, G, H, J, K 200 µm,
    Figure Legend Snippet: Panels A and B show representative examples of IHC for the hypoxia marker MCT4 in control and cabozantinib-treated tumor bearing animals. Hypoxia in compact tumor regions is significantly increased after treatment (Students t -test, p = 0.003, panel C). D and E show examples of Ki67 stainings in compact tumor areas. Proliferation indices were significantly different in these regions (Students t- test p = 0.04), but no difference was detected in diffuse tumor areas (panel F). Panels G and H show representative examples of GLUT-1 vessel staining. Automated quantification revealed no differences between vessel densities of diffuse tumor areas in control vs treated mice (I). Numbers of CD34-positive vessels were lower in cabozantinib treated mice (see panels J and K, arrows point at blood vessels), but these data were not quantified because vessels without CD34 expression were also observed in these mice. L: Western blot analysis of protein extracts (50 µg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, though not complete, reduction of c-MET phosphorylation. As a loading control, γ-tubulin was included. Immunohistochemistry for phospho-c-MET (Y1234/1235) also shows the presence of phosphorylated c-MET in treated animals, as visualized in panel K. Size bars: A–B 2 mm, D–E 100 µm, G, H, J, K 200 µm,

    Techniques Used: Marker, Staining, Expressing, Western Blot, Derivative Assay, Immunohistochemistry

    mouse monoclonal anti cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech mouse monoclonal anti cd34 antibody
    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti <t>CD34</t> antibodies. Angiogenesis was quantified by image analysis of <t>CD34</t> <t>positive</t> stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Mouse Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti cd34 antibody - by Bioz Stars, 2024-03
    93/100 stars

    Images

    1) Product Images from "Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2"

    Article Title: Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0044351

    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Figure Legend Snippet: Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Techniques Used: Injection, Isolation, Staining, Software

    mouse monoclonal anti cd34  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech mouse monoclonal anti cd34
    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti <t>CD34</t> antibodies. Angiogenesis was quantified by image analysis of <t>CD34</t> <t>positive</t> stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Mouse Monoclonal Anti Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti cd34/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti cd34 - by Bioz Stars, 2024-03
    93/100 stars

    Images

    1) Product Images from "Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2"

    Article Title: Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0044351

    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Figure Legend Snippet: Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Techniques Used: Injection, Isolation, Staining, Software

    primary cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech primary cd34 antibody
    Tumor <t>CD34</t> stainings and analysis of MVD and TVA. <t>CD34-positive</t> microvessels in the groups II (A) and VII (B) with a magnification of 100 × and scale bar of 100 μm. Density of microvessels is visibly higher in a tumor from the group II. (C) In general, MVD was lower in all the groups receiving sVEGFR2 and/or sVEGFR3 gene therapy (groups IV–VII) when compared to the groups I–III. (D) Similar to MVD results, TVA was generally lower in the groups IV–VII while difference to the group III was less prominent. Results were considered statistically significant with values of p < 0.05*, p < 0.01**, and p < 0.001***.
    Primary Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary cd34 antibody - by Bioz Stars, 2024-03
    93/100 stars

    Images

    1) Product Images from "AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice"

    Article Title: AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice

    Journal: Frontiers in Medicine

    doi: 10.3389/fmed.2022.1018208

    Tumor CD34 stainings and analysis of MVD and TVA. CD34-positive microvessels in the groups II (A) and VII (B) with a magnification of 100 × and scale bar of 100 μm. Density of microvessels is visibly higher in a tumor from the group II. (C) In general, MVD was lower in all the groups receiving sVEGFR2 and/or sVEGFR3 gene therapy (groups IV–VII) when compared to the groups I–III. (D) Similar to MVD results, TVA was generally lower in the groups IV–VII while difference to the group III was less prominent. Results were considered statistically significant with values of p < 0.05*, p < 0.01**, and p < 0.001***.
    Figure Legend Snippet: Tumor CD34 stainings and analysis of MVD and TVA. CD34-positive microvessels in the groups II (A) and VII (B) with a magnification of 100 × and scale bar of 100 μm. Density of microvessels is visibly higher in a tumor from the group II. (C) In general, MVD was lower in all the groups receiving sVEGFR2 and/or sVEGFR3 gene therapy (groups IV–VII) when compared to the groups I–III. (D) Similar to MVD results, TVA was generally lower in the groups IV–VII while difference to the group III was less prominent. Results were considered statistically significant with values of p < 0.05*, p < 0.01**, and p < 0.001***.

    Techniques Used:

    rat  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat
    Rat, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat - by Bioz Stars, 2024-03
    93/100 stars

    Images

    rat anti mouse cd34  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat anti mouse cd34
    Immunohistochemical detection of <t>CD34</t> (a vascular endothelial cell marker) and PDGFR-β (a pericyte marker) in the parabiosis model. Six to twelve ovaries were obtained from three to six wild-type mice in their natural estrous cycles. Immunostaining was evaluated on three to four tissue sections in each ovary in each developmental stage of the follicles. The developmental stages are defined in Materials and Methods. Scale bars; 50 μm.
    Rat Anti Mouse Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 - by Bioz Stars, 2024-03
    93/100 stars

    Images

    1) Product Images from "Locally existing endothelial cells and pericytes in ovarian stroma, but not bone marrow-derived vascular progenitor cells, play a central role in neovascularization during follicular development in mice"

    Article Title: Locally existing endothelial cells and pericytes in ovarian stroma, but not bone marrow-derived vascular progenitor cells, play a central role in neovascularization during follicular development in mice

    Journal: Journal of Ovarian Research

    doi: 10.1186/1757-2215-7-10

    Immunohistochemical detection of CD34 (a vascular endothelial cell marker) and PDGFR-β (a pericyte marker) in the parabiosis model. Six to twelve ovaries were obtained from three to six wild-type mice in their natural estrous cycles. Immunostaining was evaluated on three to four tissue sections in each ovary in each developmental stage of the follicles. The developmental stages are defined in Materials and Methods. Scale bars; 50 μm.
    Figure Legend Snippet: Immunohistochemical detection of CD34 (a vascular endothelial cell marker) and PDGFR-β (a pericyte marker) in the parabiosis model. Six to twelve ovaries were obtained from three to six wild-type mice in their natural estrous cycles. Immunostaining was evaluated on three to four tissue sections in each ovary in each developmental stage of the follicles. The developmental stages are defined in Materials and Methods. Scale bars; 50 μm.

    Techniques Used: Immunohistochemical staining, Marker, Immunostaining

    Double immunostaining for CD34 (a vascular endothelial cell marker) and GFP (a bone marrow derived-cell marker) in the parabiosis model. Blue shows CD34, and brown shows GFP. Double-positive cells are indicated by arrows. T: theca cell layer, G: granulosa cell layer. Scale bars; 50 μm.
    Figure Legend Snippet: Double immunostaining for CD34 (a vascular endothelial cell marker) and GFP (a bone marrow derived-cell marker) in the parabiosis model. Blue shows CD34, and brown shows GFP. Double-positive cells are indicated by arrows. T: theca cell layer, G: granulosa cell layer. Scale bars; 50 μm.

    Techniques Used: Double Immunostaining, Marker, Derivative Assay

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Hycult Biotech cd34, mouse, mab mec14.7
    Cd34, Mouse, Mab Mec14.7, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34, mouse, mab mec14.7/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34, mouse, mab mec14.7 - by Bioz Stars, 2024-03
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-03
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech cd34 antibody
    A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin). B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin). C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H). D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K). E. Macroscopical changes in paratubarian area (microscopical sections in L–N). F. Cavernous hemangioma featuring focal hyalinization. G. The same tumor mass area with higher magnification (haematoxylin-eosin). H. Weak focal hVEGF-A 165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells. I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently <t>CD34</t> <t>positive</t> lining. I. Hematoxylin-eosin. (an arrow points to an area shown in K) J. CD34 immunostaining. K. The same area as in I with higher magnification (stained with Masson Trichrom). Asterix in I and J indicate the same area. L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A 165 immunopositivity shown in N. (hVEGF-A 165 immunostaining). Bar : F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.
    Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34 antibody - by Bioz Stars, 2024-03
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech cd34
    Panels A and B show representative examples of IHC for the hypoxia marker MCT4 in control and cabozantinib-treated tumor bearing animals. Hypoxia in compact tumor regions is significantly increased after treatment (Students t -test, p = 0.003, panel C). D and E show examples of Ki67 stainings in compact tumor areas. Proliferation indices were significantly different in these regions (Students t- test p = 0.04), but no difference was detected in diffuse tumor areas (panel F). Panels G and H show representative examples of GLUT-1 vessel staining. Automated quantification revealed no differences between vessel densities of diffuse tumor areas in control vs treated mice (I). Numbers of <t>CD34-positive</t> vessels were lower in cabozantinib treated mice (see panels J and K, arrows point at blood vessels), but these data were not quantified because vessels without <t>CD34</t> expression were also observed in these mice. L: Western blot analysis of protein extracts (50 µg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, though not complete, reduction of c-MET phosphorylation. As a loading control, γ-tubulin was included. Immunohistochemistry for phospho-c-MET (Y1234/1235) also shows the presence of phosphorylated c-MET in treated animals, as visualized in panel K. Size bars: A–B 2 mm, D–E 100 µm, G, H, J, K 200 µm,
    Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34 - by Bioz Stars, 2024-03
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech mouse monoclonal anti cd34 antibody
    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti <t>CD34</t> antibodies. Angiogenesis was quantified by image analysis of <t>CD34</t> <t>positive</t> stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Mouse Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti cd34 antibody - by Bioz Stars, 2024-03
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech mouse monoclonal anti cd34
    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti <t>CD34</t> antibodies. Angiogenesis was quantified by image analysis of <t>CD34</t> <t>positive</t> stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Mouse Monoclonal Anti Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti cd34/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti cd34 - by Bioz Stars, 2024-03
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech primary cd34 antibody
    Tumor <t>CD34</t> stainings and analysis of MVD and TVA. <t>CD34-positive</t> microvessels in the groups II (A) and VII (B) with a magnification of 100 × and scale bar of 100 μm. Density of microvessels is visibly higher in a tumor from the group II. (C) In general, MVD was lower in all the groups receiving sVEGFR2 and/or sVEGFR3 gene therapy (groups IV–VII) when compared to the groups I–III. (D) Similar to MVD results, TVA was generally lower in the groups IV–VII while difference to the group III was less prominent. Results were considered statistically significant with values of p < 0.05*, p < 0.01**, and p < 0.001***.
    Primary Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary cd34 antibody - by Bioz Stars, 2024-03
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech rat
    Tumor <t>CD34</t> stainings and analysis of MVD and TVA. <t>CD34-positive</t> microvessels in the groups II (A) and VII (B) with a magnification of 100 × and scale bar of 100 μm. Density of microvessels is visibly higher in a tumor from the group II. (C) In general, MVD was lower in all the groups receiving sVEGFR2 and/or sVEGFR3 gene therapy (groups IV–VII) when compared to the groups I–III. (D) Similar to MVD results, TVA was generally lower in the groups IV–VII while difference to the group III was less prominent. Results were considered statistically significant with values of p < 0.05*, p < 0.01**, and p < 0.001***.
    Rat, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat - by Bioz Stars, 2024-03
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech rat anti mouse cd34
    Immunohistochemical detection of <t>CD34</t> (a vascular endothelial cell marker) and PDGFR-β (a pericyte marker) in the parabiosis model. Six to twelve ovaries were obtained from three to six wild-type mice in their natural estrous cycles. Immunostaining was evaluated on three to four tissue sections in each ovary in each developmental stage of the follicles. The developmental stages are defined in Materials and Methods. Scale bars; 50 μm.
    Rat Anti Mouse Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 - by Bioz Stars, 2024-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Journal: bioRxiv

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    doi: 10.1101/2023.01.08.523169

    Figure Lengend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Article Snippet: Polyclonal rabbit anti-MCM6 (Proteintech, 13347-2-AP) and polyclonal rabbit anti-TIF1B/KAP1 (Merck Millipore, Sigma-Aldrich, ABE1859), mouse monoclonal anti-ICBP90/UHRF1 (Sigma-Aldrich, MABE308), rat monoclonal anti-HA-Peroxidase high affinity (Roche, Sigma-Aldrich, 12013819001), rabbit polyclonal anti-Actin (Sigma-Aldrich, A2103), mouse monoclonal anti-FLAG® M2-Peroxidase (Sigma-Aldrich, A8592), mouse monoclonal anti-Tropomyosin Ab (Sigma-Aldrich, T2780), goat polyclonal anti-rabbit IgG–Peroxidase antibody (Sigma-Aldrich, A6154), Alexa Fluor® 488 Goat Anti-Mouse IgG antibody (Molecular Probes, Invitrogen, A-11001, A11029), Alexa Fluor® 594 Goat Anti-Rabbit IgG antibody (Molecular Probes, Invitrogen, A-11012), Fluoroshield™ with DAPI (Sigma-Aldrich, F6057), Dynabeads™ CD25 (Invitrogen, Thermo Ficher Scientific, 11157D), rat monoclonal anti-CD34 antibody (HycultBiotech, HM1015), Polink-2 Plus HRP Rat-NM Bulk kit for DAB (GBI Labs, D46-110), rabbit monoclonal anti-Ki67 (Neomarkers; LabVision, Thermo Fisher Scientific, RM-9106), rabbit polyclonal cleaved Caspase-3 (Asp175) (Cell Signaling, 9661), anti-FLAG M2 affinity gel (Sigma-Aldrich, A 2220), FLAG® Peptide (Sigma-Aldrich, F3290), Protein A agarose (Pierce, Thermo Ficher Scientific, 20333).

    Techniques: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin). B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin). C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H). D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K). E. Macroscopical changes in paratubarian area (microscopical sections in L–N). F. Cavernous hemangioma featuring focal hyalinization. G. The same tumor mass area with higher magnification (haematoxylin-eosin). H. Weak focal hVEGF-A 165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells. I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently CD34 positive lining. I. Hematoxylin-eosin. (an arrow points to an area shown in K) J. CD34 immunostaining. K. The same area as in I with higher magnification (stained with Masson Trichrom). Asterix in I and J indicate the same area. L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A 165 immunopositivity shown in N. (hVEGF-A 165 immunostaining). Bar : F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.

    Journal: PLoS ONE

    Article Title: Short and Long-Term Effects of hVEGF-A 165 in Cre-Activated Transgenic Mice

    doi: 10.1371/journal.pone.0000013

    Figure Lengend Snippet: A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin). B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin). C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H). D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K). E. Macroscopical changes in paratubarian area (microscopical sections in L–N). F. Cavernous hemangioma featuring focal hyalinization. G. The same tumor mass area with higher magnification (haematoxylin-eosin). H. Weak focal hVEGF-A 165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells. I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently CD34 positive lining. I. Hematoxylin-eosin. (an arrow points to an area shown in K) J. CD34 immunostaining. K. The same area as in I with higher magnification (stained with Masson Trichrom). Asterix in I and J indicate the same area. L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A 165 immunopositivity shown in N. (hVEGF-A 165 immunostaining). Bar : F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.

    Article Snippet: Tissue vascularization was assessed by immunostaining with CD34 antibody (HyCult biotechnology BV, clone MEC 14.7, dilution 1∶20).

    Techniques: Immunostaining, Staining

    Panels A and B show representative examples of IHC for the hypoxia marker MCT4 in control and cabozantinib-treated tumor bearing animals. Hypoxia in compact tumor regions is significantly increased after treatment (Students t -test, p = 0.003, panel C). D and E show examples of Ki67 stainings in compact tumor areas. Proliferation indices were significantly different in these regions (Students t- test p = 0.04), but no difference was detected in diffuse tumor areas (panel F). Panels G and H show representative examples of GLUT-1 vessel staining. Automated quantification revealed no differences between vessel densities of diffuse tumor areas in control vs treated mice (I). Numbers of CD34-positive vessels were lower in cabozantinib treated mice (see panels J and K, arrows point at blood vessels), but these data were not quantified because vessels without CD34 expression were also observed in these mice. L: Western blot analysis of protein extracts (50 µg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, though not complete, reduction of c-MET phosphorylation. As a loading control, γ-tubulin was included. Immunohistochemistry for phospho-c-MET (Y1234/1235) also shows the presence of phosphorylated c-MET in treated animals, as visualized in panel K. Size bars: A–B 2 mm, D–E 100 µm, G, H, J, K 200 µm,

    Journal: PLoS ONE

    Article Title: Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2

    doi: 10.1371/journal.pone.0058262

    Figure Lengend Snippet: Panels A and B show representative examples of IHC for the hypoxia marker MCT4 in control and cabozantinib-treated tumor bearing animals. Hypoxia in compact tumor regions is significantly increased after treatment (Students t -test, p = 0.003, panel C). D and E show examples of Ki67 stainings in compact tumor areas. Proliferation indices were significantly different in these regions (Students t- test p = 0.04), but no difference was detected in diffuse tumor areas (panel F). Panels G and H show representative examples of GLUT-1 vessel staining. Automated quantification revealed no differences between vessel densities of diffuse tumor areas in control vs treated mice (I). Numbers of CD34-positive vessels were lower in cabozantinib treated mice (see panels J and K, arrows point at blood vessels), but these data were not quantified because vessels without CD34 expression were also observed in these mice. L: Western blot analysis of protein extracts (50 µg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, though not complete, reduction of c-MET phosphorylation. As a loading control, γ-tubulin was included. Immunohistochemistry for phospho-c-MET (Y1234/1235) also shows the presence of phosphorylated c-MET in treated animals, as visualized in panel K. Size bars: A–B 2 mm, D–E 100 µm, G, H, J, K 200 µm,

    Article Snippet: In short, after epitope retrieval by boiling in citrate buffer (pH 6.0), 4 µm tissue sections were incubated with primary antibodies against GLUT1 (Neomarkers), CD34 (clone MEC14.7, Hycult biotech), c-MET (clone EP1454Y, Epitomics), phospho-c-MET (Y1234/1235, clone D26, CST), MCT4 (clone H90, Santa Cruz), cleaved caspase 3A (clone C92-605, BD Pharmingen) and Ki-67 (clone Sp6, Thermo Fisher Scientific).

    Techniques: Marker, Staining, Expressing, Western Blot, Derivative Assay, Immunohistochemistry

    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Journal: PLoS ONE

    Article Title: Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2

    doi: 10.1371/journal.pone.0044351

    Figure Lengend Snippet: Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Article Snippet: To visualize endothelial cells within the tumors, sections were incubated with mouse monoclonal anti-CD34 antibody (Hycult Biotech, The Netherlands) during 1 hour at 37°C in a humidity chamber.

    Techniques: Injection, Isolation, Staining, Software

    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Journal: PLoS ONE

    Article Title: Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2

    doi: 10.1371/journal.pone.0044351

    Figure Lengend Snippet: Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Article Snippet: Mouse monoclonal anti-CD34 was from Hycult Biotech (The Netherlands), secondary antibody, rabbit anti-rat IgG was obtained from Southern Biotech (Clinisciences; France).

    Techniques: Injection, Isolation, Staining, Software

    Tumor CD34 stainings and analysis of MVD and TVA. CD34-positive microvessels in the groups II (A) and VII (B) with a magnification of 100 × and scale bar of 100 μm. Density of microvessels is visibly higher in a tumor from the group II. (C) In general, MVD was lower in all the groups receiving sVEGFR2 and/or sVEGFR3 gene therapy (groups IV–VII) when compared to the groups I–III. (D) Similar to MVD results, TVA was generally lower in the groups IV–VII while difference to the group III was less prominent. Results were considered statistically significant with values of p < 0.05*, p < 0.01**, and p < 0.001***.

    Journal: Frontiers in Medicine

    Article Title: AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice

    doi: 10.3389/fmed.2022.1018208

    Figure Lengend Snippet: Tumor CD34 stainings and analysis of MVD and TVA. CD34-positive microvessels in the groups II (A) and VII (B) with a magnification of 100 × and scale bar of 100 μm. Density of microvessels is visibly higher in a tumor from the group II. (C) In general, MVD was lower in all the groups receiving sVEGFR2 and/or sVEGFR3 gene therapy (groups IV–VII) when compared to the groups I–III. (D) Similar to MVD results, TVA was generally lower in the groups IV–VII while difference to the group III was less prominent. Results were considered statistically significant with values of p < 0.05*, p < 0.01**, and p < 0.001***.

    Article Snippet: The samples were then blocked with serum (1:10 diluted goat serum and 1:50 diluted mouse serum) at room temperature, before being incubated with monoclonal primary CD34 antibody (1:50 dilution, MEC 14.7, HM1015, Hycult Biotech, Uden, the Netherlands) overnight in 4°C in humid chamber.

    Techniques:

    Immunohistochemical detection of CD34 (a vascular endothelial cell marker) and PDGFR-β (a pericyte marker) in the parabiosis model. Six to twelve ovaries were obtained from three to six wild-type mice in their natural estrous cycles. Immunostaining was evaluated on three to four tissue sections in each ovary in each developmental stage of the follicles. The developmental stages are defined in Materials and Methods. Scale bars; 50 μm.

    Journal: Journal of Ovarian Research

    Article Title: Locally existing endothelial cells and pericytes in ovarian stroma, but not bone marrow-derived vascular progenitor cells, play a central role in neovascularization during follicular development in mice

    doi: 10.1186/1757-2215-7-10

    Figure Lengend Snippet: Immunohistochemical detection of CD34 (a vascular endothelial cell marker) and PDGFR-β (a pericyte marker) in the parabiosis model. Six to twelve ovaries were obtained from three to six wild-type mice in their natural estrous cycles. Immunostaining was evaluated on three to four tissue sections in each ovary in each developmental stage of the follicles. The developmental stages are defined in Materials and Methods. Scale bars; 50 μm.

    Article Snippet: The primary antibodies used in the enzyme-based immunohistochemistry were rat anti-mouse CD34 (an endothelial cell marker; HM1015; Hycult Biotechnology, Uden, the Netherlands, dilution 1/50) and rabbit anti-PDGFR-β antibodies (dilution 1/1000).

    Techniques: Immunohistochemical staining, Marker, Immunostaining

    Double immunostaining for CD34 (a vascular endothelial cell marker) and GFP (a bone marrow derived-cell marker) in the parabiosis model. Blue shows CD34, and brown shows GFP. Double-positive cells are indicated by arrows. T: theca cell layer, G: granulosa cell layer. Scale bars; 50 μm.

    Journal: Journal of Ovarian Research

    Article Title: Locally existing endothelial cells and pericytes in ovarian stroma, but not bone marrow-derived vascular progenitor cells, play a central role in neovascularization during follicular development in mice

    doi: 10.1186/1757-2215-7-10

    Figure Lengend Snippet: Double immunostaining for CD34 (a vascular endothelial cell marker) and GFP (a bone marrow derived-cell marker) in the parabiosis model. Blue shows CD34, and brown shows GFP. Double-positive cells are indicated by arrows. T: theca cell layer, G: granulosa cell layer. Scale bars; 50 μm.

    Article Snippet: The primary antibodies used in the enzyme-based immunohistochemistry were rat anti-mouse CD34 (an endothelial cell marker; HM1015; Hycult Biotechnology, Uden, the Netherlands, dilution 1/50) and rabbit anti-PDGFR-β antibodies (dilution 1/1000).

    Techniques: Double Immunostaining, Marker, Derivative Assay